Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Abstract

Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Rogers et al. used a high-throughput pipeline to isolate and characterize monoclonal antibodies from convalescent donors. Antibodies were selected for binding to the viral spike protein, which facilitates entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. Most isolated antibodies bound to regions of the spike outside of the receptor binding domain (RBD); however, a larger proportion of the RBD-binding antibodies were neutralizing, with the most potent binding at a site that overlaps the ACE2 binding site. Two of the neutralizing antibodies were tested in Syrian hamsters and provided protection against SARS-CoV-2 infection. Science , this issue p. 956

Keywords

MeSH Terms

Affiliated Institutions

• International AIDS Vaccine Initiative US
• George Washington University US
• Scripps Research Institute US
• Ragon Institute of MGH, MIT and Harvard US
• La Jolla Institute for Immunology US
• University of California, San Diego US

Related Publications